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Solubilization of dopamine receptors, in a native 
form, was first achieved in our laboratory using dog 
striatum and the mild detergent digitonin [l-3]. 
These results were confirmed by another group in 
both dog and human brain [4f. However, earlier 
attempts to solubilize dopamine receptors from rat 
striatum were ~s~essfui~ even though a similar 
experimental procedure was used [3,5]. Although 
the binding properties of dopamine receptors in 
striatal membrane preparations were identical in both 
animals, the discrepancy between the data from rat 
and dog remained unexplained [3], This study was 
undertaken to solve the problem. 
The results how that the solubilized opamine 
receptors from rat striatum are masked by a high 
number of non-specific but displaceable spiperone 
binding sites. These binding sites have been already 
described in membrane preparations as non-stereo- 
specific or spirod~anone sites (cf. Gg.2) [6,7]. The 
use of a compound which is s~uct~a~y related to 
spiperone, but is inactive on dopamine receptors 
enabled us to determine and characterize solubilized 
dopamine receptors from the rat striatum, by means 
of the charcoal assay method. 
2, Materials and methods 
Wistar ats were decapitated, mongreI dogs and 
cats were anaesthetized with pentobarbital; their 
brains were dI~ected~ut and homogenized in 0.25 
M ice-cold sucrose. After preparation of the micro- 
somal fraction f8], which may be kept at -16”C, the 
extraction was performed at 0°C with 1% digitonin 
K’kevicrr/North -Ho&and Biomedical Press 
suspended in4 vol. 0.25 M sucrose containing 10 mM 
sodium phosphate (pH 7.2) and 0.02% NaNa, and 
supplemented by I mM EDTA, 1 mM EGTA and 0.1 
mM phenylmethylsulfonylfluoride (PMSF) to prevent 
proteolytic degradation. The radiochemical purity 
(95-98%) of the fsH] spiperone (25.5 Cijmmol and 
23.6 and 25.7 Cilmmol, respectively from IRE, 
Fleurus, Belgium and NEN, Boston, MA) was con- 
trolled by thin-layer chromatography on silicagel 
plates developed with benzene-et~ol-~~~H 
(85:10:0.5, by vol.). Incubations were at 0°C for 16 
h. The Sephadex G-50 assay method was used as in 
[S]. The charcoal and ammonium sulphate techniques 
were as in [9]. The equilibrium dialysis was carried 
out using a Dianorm dialyser (Diachem, Zurich) 
equiped with pairs of 1 ml teflon cells, mounted with 
a Spectra Por 2 membrane (Spectrum Medical 
Industries, Los Angeles, CA). Specific binding was 
defined as the difference between the binding of 
t3H]spiperone (2 X 10” M) with or without 1Oa M 
f+)-butaclamol, 
3. ResuISs and discussion 
The failure of digitonin to solubilize dopamine 
receptors from rat striatum could be explained either 
by a proteolytic degradation, orby a nonappropriate 
detection by gel filtration. Therefore, in a first 
approach, using striatal dog preparations as reference 
system 12-41, extraction was in the presence of 
inhibitors of proteolysis and determ~ations of the 
specific binding sites were performed with different 
assay techniques. 
To assess the specificity of each procedure, three 
different parameters (table 1) were considered: the 
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Table 1 
[ SH]Spiperone binding measured using different assay methods with a solubilized preparation from dog striatum 
A. Sephadex G-50 
B . Charcoal 
C. (NH&SO, 
D. Dialysis 
KY,,-valuea (M) 
(+)-Butaclamol 
3.0 x lo-* 
3.4 x 1o-8 
1.7 x lo-* 
- 
Bindingb (fmol/ml) Buffer blank 
(% specific 
(-)-Butaclamol Specific Non-specific binding) 
7.9 x 10-6. 357 i 19 11.5 * 11 3.4 
6.3 x 1O-6 505 4 12 1025 1.3 2.2 
4.0 x 1o-6 185 * 4.2 47 f 1.3 52 
205 + 26 2038 + 50 22 
a IC,,-values were determined from competition experiments using 7 concentrations (10“’ -f0-4 M) of (+)-and (-)-butaclamol 
b Binding was expressed as the mean value i SEM (A, n = 3; B-D, n = 4) 
stereospecificity (&,-values for (-I-)- and (-)-buta- 
clamol) and the relative amounts of specific and non- 
specific binding. Table 1 shows that a similar stereo- 
specific effect was obtained with the gel filtration, 
charcoal and ammonium sulphate methods; indeed 
the (-l/(t)-butaclamol KS,-ratios ranged from 1 g5- 
260, being thus similar to those found in the corre- 
sponding membrane preparations [3,10]. When one 
examines the specific vs non-specific binding, it is 
obvious that the equihbri~ dialysis method suffered 
from higher non-specific binding 191% of the total). 
The ammonium sulphate method yielded the lowest 
amount of specific binding (only 37% of that obtained 
by the charcoal method). Moreover its buffer blank 
(binding measured when buffer replaced the soluble 
extract) was also high. The Sephadex G-SO and the 
charcoal methods yielded high specific binding, con- 
comitant with low non-specific binding. The charcoal 
assay method may be considered as the most appro- 
priate technique, since it gives a high yield, is easy to 
perform, is not tie-consuming, and is quite repro- 
ducible. This method was therefore applied to solu- 
bilized extracts from rat striatum. 
Fig. 1 shows that the displacement of 13H] spiperone 
by (t)-butaclamol in soluble extracts from rat stria- 
turn revealed abiphasic urve when the ligand-recep- 
tor complex was measured by the charcoal technique. 
Such a curve was never obtained after gel filtration 
(cf. also the (t)-butaclamol displacement curve in [5] ). 
The first slope between lo-‘-10” M probably corre- 
sponds to the specific binding and the second slope 
between 1O6-1OA M to a non-specific but displace- 
able binding. Interestin~y the inflection point at 
1Oa M (~~-butaclamol was repeatedly found in dif- 
ferent experiments. Contrary to (-I-)-butaclamol, 
spiperone was found to displace both types of bind- 
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Fig.1. Competition curves of spiperone (SPIP) and the 
butaclamol (BUT) enantiomers for digitonin-solubilized 
preparations incubated with 2 X 1O-9 M [“Hlspiperone. The 
full lines represent he results obtained using the charcoal 
assay method, the dashed line those obtained for (+)-buta- 
clam01 using the gel filtration method. Each point is the 
mean value of two determinations. Arrows indicate the blank 
values with lo-’ M (+)-butaclamol r spiperone and after 
thermal ~activation (56“C, 10 min). The iC,,-values for 
spiperone, (+)-butac~mol and (-)-butac~o1 were, respec- 
tively, 2 X lo-* M, 2.8 X lo-” M and 1O-5 M when (+)- 
butaclamol (lo-* M) was used as blank and of 1.4 X lo-* M, 
2.7 x 1O-6 M and 1.4 x 1O-4 M when spiperone (10e6 M) 
or thermal inactivation were used as blanks. 
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ing sites according a monop~sic com~tition curve. 
In our earlier experiments on rat preparations the 
blank values (non-specific binding) were determined 
either by competition of 10P6 M spiperone [5] or 
after thermal inactivation [3]. In fact the use of 
(t)-butaclamol for the blank is preferable to the use 
of unlabelled spiperone, because the latter can also 
displace non-specific binding, presumably from the 
spirodecanone sites. For instance fig.1 shows that if 
10” M spiperone is taken as blank, the apparent 
affinity of (~)-butacl~ol (K$e-value) is in the @I 
range, whilst it is -10 nM when the non-specific 
binding is determined using 10” M (+)-butaclamol. 
The same argument is valid for the thermal inactiva- 
tion which affects both specific dopaminergic and 
spirodecanone sites. 
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Fig.2. Comparison of the chemical structures of R 5260, 
spiperone (spiroperidol) and benperidol. 
To prevent such non-specific bindlng we selected gic activity [3,11]. Both drugs were compared, in 
a compound, R 5260 (potent analgesic [ 111) which different binding experiments o benperidol 
possesses the spirodecanone moiety like spiperone (fig.3A,B), one of the most potent dopamine antago- 
(frg.2), but which is completely devoid of dopaminer- nists [3,11 J, which is a butyrophenone like spiperone 
s 
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Fig.3. Competition curves of various drugs in solubilized preparations from dog and rat striata, after ~~ubation with 2 X ID-’ &I 
[3H]spiperone. (A) Spiperone f-X- - -1, benperidol (-A-) and R 5260 (-•-) curves using striataf dog extracts (as in [Z]) and 
the gel filtration technique. (B) Competition of the same drugs in the striatal rat extracts (as in [3,5]) using the gel filtration tech- 
nique. An arrow indicates the displacement at lo-’ M R 5260. (C) Competition curves of benperidol using the charcoal assay in 
the presence or the absence of lo-’ M R 5260. The IC,,-values of benperidol were, respectively, 2.5 X lob9 M (+ R 5260) and 
5.8 X 1O-9 M (- R 5260). 
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Table 2 
(3H&Spiperone bind&$ in striatal extracts from ~ariaus species with or without R 5260 at 10-’ M 
rc,,=valueb (MI Binding ffmol/mlj 
- 
(+)-Butaclamol (-)-Buta- Ambro- Specific Non-specific 
clam01 tetrahn -~ 
- R 5260 + R 5260 derivative 1-R 5260 + R 5260 - R 5260 + R 5260 
Jml 1.4 x lo-* 0.8 x 1O-s 6 x IO-@ 2.2 x IO“ 557 436 105 85 
Cat 1.0 x 10-s 1.7 x lo-* 14 x 10-6 2.8 x lo-’ 294 236 150 121 
Rat 0.9 x 1o-s 0.9 x 1o-8 14 x lcPc 1.3 x lo-‘C 175 178 590 266 
a Binding was determined in duplicate 
b ICso-values were determined by competition apainst i3H]spiperone (2 X 10-s M) using 7 concentrations (10-‘0-10-4 M) of (+)- 
and (-)~utacl~~ and the ~~otetr~ derivative 
’ Binding measured in the presence of R 5260 at 10-s M 
but does not possess the spirodecanone moiety 
(tig.2). Fig3A shows that for solubilizeh striatal 
preparations from dog, assayed with the gel filtration 
method, spiperone and benperidol campeted with 
[sH]spiperone at very low concentrations, while R 
5260 was inactive at lo-’ M. In contrast o this, 
solubilized preparations from rat striatum, measured 
with the same assay method, displayed ahigh affinity 
towards piperone but a low one for benperidol, 
whereas R 5260 was found to compete with f&H]- 
spiperone at 10 d M (fig33). As shown in fig3C the 
displacement curve of benperidol obtained in rat 
extracts by using the charcoal method, displayed a
marked biphasic profile in the absence of R 5260. At 
10s5 M this compound, used to block the spirodeca- 
none sites, converts this competitition curve of 
benperidol into a classical monophasic displacement 
curve. Therefore the use of such a drug as R 5260 at 
an appropriate concentration, combined with the 
charcoal assay method, markedly improved the 
detection of the specific binding in solubilized prepa- 
rations of rat striatum. This procedure was now 
applied to characterize the [eH]spiperone binding 
sites in solubilized preparations from rat striatum, 
and then to compare them to the results obtained 
with other species. 
Table 2 shows that (t)-butaclamol and the potent 
dopamine agonist (It) 2-(NJ-dipropyl)amino-5,6- 
dihydroxytetralin (ATL) revealed ahigh affinity in 
rat preparations, their respective ZCse+%lues being 
comparable to those already obtained in membrane 
preparations from rat and dog striatum [3&O], as in 
solubilized pre~rations from dog and cat. Table 2 
shows also that R 5260 at IO” M did not markedly 
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affect the ZCse-value of (~~butaclamol in the differ- 
ent mammalian preparations. However, it was found 
to tremendously decrease the non-specific binding in 
rat preparations without altering the specific binding, 
whereas in cat and dog the low non-specific binding 
level remained almost unchanged, whilst the specific 
4 
l R 5260 
Fig.4. Variation of the apparent specific (----) and nonspe- 
cific (---) [ ‘HJspiperone binding in the presence (o&I or 
the absence (e$) of R 5260, with increasing (+)-butaclamol 
concentrations used for the determination of the blank val- 
ues. Each point comes from (~~-buta~amo~ competition 
curves performed in duplicate with rat striatal sofubibaed prep- 
arations, 
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Fig.5. Gradient sedimentation profiles of dopamine and mus- 
carinic receptors from a digitonin extract of rat St&turn.- 
Soluble extract (1 ml) was layered on a U-30% sucrose 
gradient containing 10 mM sodium phosphate (pH 7.2), 
0.02% NaN, and 0.03% digitonin, and-then centrifuged at 
152 000 X g (rav) for 20 h with a SW4OTi rotor (Spinco) at 
2°C. The dopamine receptor was measured in the presence 
of lo-’ M R 5260, using 2 X 10e9 M [3H]spiperone (53 
Ci/mmol, NEN) with 1O-6 M (+)-butaclamol for the blank, 
while the muscarinic receptor did using 2 X 10s9 M [3H]- 
dexetimide (17 Ci/mmol, IRE) with 2 X lo-’ M unlabelled 
dexetimide for the blank. The charcoal method was used for 
both receptor determinations. 
binding decreased by -20%. Consequently in rat prep- 
arations, the choice of an appropriate blank is of 
great importance, because of the high amount of non- 
specific binding. When R 5260 blocks these spiro- 
decanone sites (fig.4) both the specific and the non- 
specific binding remained constant with (t)-butacla- 
mol at l-10 PM. In contrast, in the absence of this 
drug the apparent specific binding rose with increasing 
(t)-butaclamol concentrations, concomitantly the 
apparent non-specific binding decreased. Conse- 
quently, the use of R 5260 seriously improves the 
safety of measurement of the specific dopaminergic 
binding sites and must be strongly recommended for 
rat striatal extracts. Nevertheless when the spiro- 
decanone binding is relatively low, for instance in cat 
and dog, the use of this compound is not necessary. 
That more spirodecanone sites were found in the 
rat than in the corresponding preparations from dog 
is probably only the result of species variability. In 
addition to this difference between species, the 
amount of spirodecanone sites was much higher in 
the frontal cortex than in the striatum (cf. fig.la,b 
of [6]); this repartition is incompatible with the 
regional distribution of dopamine receptors. A further 
difference between both sites is that a significant 
amount of spirodecanone sites, but not of dopamine 
receptors, was found in a soluble form when the pro- 
cedure was carried out in the absence of the detergent 
(unpublished). Finally the spirodecanone sites are not 
relevant for any known pharmacological activity [7]. 
A similar phenomenon dealing with displaceable non- 
specific binding was recently reported in studies on 
fl-adrenergic [ 121 and benzodiazepine [ 131 receptors. 
This problem also represented the main difficulty _ 
when studying the solubilization of serotonin 
receptors by lysolecithin (in preparation). 
The solubilized opamine receptor sites from rat 
striatum were further characterized by sedimentation 
gradient. Fig.5 shows the sedimentation profile of the 
specific [3H]spiperone binding compared to that of 
the muscarinic receptor labelled by [3H]dexetimide 
[ 141. The position of both peaks is quite similar to 
that reported in the striatal dog preparations [2], 
which suggests an interspecies molecular homogeneity 
for dopaminergic sites. 
From the above experiments, evidence is provided 
for the solubilization of a high-affinity dopamine 
receptor from rat striatum. If the non-specific binding 
can be reduced and if an appropriate assay method is 
used, solubilized receptors labelled by [3H]spiperone 
may be identified as being of dopaminergic nature 
both by their binding and by their hydrodynamic 
characteristics. 
That a similar dopaminergic macromolecular com- 
plex was extracted from the brain of different species 
(dog [2-41, human [4], cat and rat) using the same 
detergent, strongly favors the unitary concept of 
receptor systems. Since this macromolecular receptor 
complex has been extracted by a mild detergent, 
digitonin, it may belong to the class of the intrinsic 
bound membrane proteins [ 151. These concordant 
facts from different studies on various pecies, are in 
discordant disagreement with reports on the solubili- 
zation of dopamine receptor sites from calf striatum 
[ 16,171, treated with high concentrations of salt 
(50-500% KCl). A similar discrepancy between the 
solubilization of the muscarinic receptor either by 
digitonin, or by salt (2 M NaCl) was recently resolved 
by demonstrating that the salt extraction resulted in 
an ‘artefactual’ solubilization of the muscarinic recep- 
tor [ 181. This same question may be asked of the salt- 
solubilized opamine receptor sites from calf striatum. 
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